Apellis Pharmaceuticals
$47.60
24H
Market Cap
Volume
Supply
Price Chart
About Apellis Pharmaceuticals - APLS
Apellis Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel therapies to treat a range of autoimmune and inflammatory diseases. They are known for their research into complement inhibitors, particularly targeting the C3 protein, to address diseases with high unmet medical need.
What are Apellis Pharmaceuticals's core values and mission statement?
Apellis Pharmaceuticals, Inc. is dedicated to pioneering targeted C3 therapies with the goal of developing transformative treatments for patients with serious diseases. Their core values are grounded in innovation, collaboration, and a commitment to patients.
Who founded Apellis Pharmaceuticals and when?
Apellis Pharmaceuticals, Inc. was founded by Cedric Francois and Pascal Deschatelets in 2009.
Who leads Apellis Pharmaceuticals?
As of the last update, the CEO of Apellis Pharmaceuticals, Inc. is Cedric Francois.
Where is Apellis Pharmaceuticals located, and what is its base country?
Apellis Pharmaceuticals, Inc. is headquartered in Waltham, Massachusetts, USA. Its base country is the United States.
On which exchanges is Apellis Pharmaceuticals traded?
Apellis Pharmaceuticals, Inc. is traded on the Nasdaq Stock Market under the ticker symbol APLS.
Historical data
Apellis Pharmaceuticals (APLS) Price Live Data
The live price of Apellis Pharmaceuticals (APLS) is $47.60, with a trading volume of 955,812 in the last 24 hours. Wrapstocks updates the APLS price in real-time. Apellis Pharmaceuticals is up 0.19% in the last 24 hours. The company has a live market cap of $5,739,702,784.00 and a supply of 120,581,991 APLS stocks.
Apellis Pharmaceuticals (APLS) is traded on NASDAQ Stock Exchange, and currently, the market is closed; trading will be resumed in 4 hours and 10 minutes.
